Gruber Sarah F, Schwinne Megan, Iytha Rishika, Hollenberg Emma J, Robichaux Chad, Cantos Valeria D, Colasanti Jonathan A, Yaffee Anna Q, Turbow Sara, Leue Eric, Camacho-González Andrés, Wang Yun F, Lora Meredith H
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, Georgia, USA.
Open Forum Infect Dis. 2025 Aug 26;12(8):ofaf423. doi: 10.1093/ofid/ofaf423. eCollection 2025 Aug.
Routine, opt-out HIV testing strategies aim to diagnose HIV earlier and decrease ongoing transmission. We report missed opportunities (MO) and missed testing opportunities (MTO) for earlier HIV diagnosis in a safety-net healthcare system using routine opt-out testing.
This retrospective study analyzed adults diagnosed with HIV between 2015 and 2022 with eligible encounters 30-365 days before diagnosis. MO is defined as no HIV testing in the year before diagnosis. MTOs are encounters where testing was indicated but not performed. Logistic regression identified factors associated with MO and MTO. To evaluate the opt-out testing program, we measured the number of individuals eligible for testing, tests completed, reactive results, and new HIV diagnoses.
Of 713 newly diagnosed individuals, 499 (70%) had MO. Among 1845 encounters, 1235 (67%) were MTO. Sexual health-related encounters and STI testing had lower MO odds (adjusted odds ratio [aOR] 0.62; 95% confidence interval [CI], 0.42-0.90; = .013) and (aOR 0.36; 95% CI, 0.28-0.48; < .0001), respectively. MO was associated with higher odds of CD4 < 350 cells/mm at diagnosis (aOR 1.8; 95% CI, 1.2-2.9; = .011). Outpatient encounters, particularly primary care, had higher MTO odds than emergency department (OR 0.67; 95% CI, 0.54-0.82; < .0001). Among 531,848 eligible individuals, 357,771 tests were conducted in 199,004 individuals (37.4%); 4719 (1.3%) tests were reactive, resulting in 861 (0.4%) new HIV diagnoses.
Despite routine opt-out HIV testing, most individuals newly diagnosed with HIV had no testing in the prior year, highlighting the need to optimize opt-out testing procedures, particularly in primary care and nonsexual health visits.
常规的选择退出式HIV检测策略旨在更早地诊断HIV并减少持续传播。我们报告了在一个使用常规选择退出式检测的安全网医疗系统中,早期HIV诊断的错失机会(MO)和错失检测机会(MTO)情况。
这项回顾性研究分析了2015年至2022年间被诊断为HIV的成年人,这些成年人在诊断前30 - 365天有符合条件的就诊经历。MO被定义为在诊断前一年未进行HIV检测。MTO是指有检测指征但未进行检测的就诊情况。逻辑回归确定了与MO和MTO相关的因素。为了评估选择退出式检测项目,我们测量了符合检测条件的个体数量、完成的检测数量、阳性结果以及新的HIV诊断数量。
在713名新诊断的个体中,499名(70%)有MO。在1845次就诊中,1235次(67%)是MTO。与性健康相关的就诊和性传播感染检测的MO几率较低(调整后的优势比[aOR]为0.62;95%置信区间[CI],0.42 - 0.90;P = 0.013)和(aOR为0.36;95% CI,0.28 - 0.48;P < 0.0001)。MO与诊断时CD4 < 350个细胞/mm³的较高几率相关(aOR为1.8;95% CI,1.2 - 2.9;P = 0.011)。门诊就诊,尤其是初级保健,MTO几率高于急诊科(OR为0.67;95% CI,0.54 - 0.82;P < 0.0001)。在531,848名符合条件的个体中,对199,004名个体(37.4%)进行了357,771次检测;4719次(1.3%)检测呈阳性,导致861例(0.4%)新的HIV诊断。结论:尽管采用了常规的选择退出式HIV检测,但大多数新诊断为HIV的个体在前一年未进行检测,这突出表明需要优化选择退出式检测程序,特别是在初级保健和非性健康就诊中。